Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deborah Shapiro

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
The New England Journal of Medicine|March 18, 2006
Response to expression of concern regarding VIGOR studyAlise Reicin, Deborah Shapiro
Adapted Physical Activity Quarterly : APAQ|February 29, 2024
The Palgrave Handbook of Disability Sport in Europe: Policies, Structures, and ParticipationWellington De Luna-Vazquez, Deborah Shapiro
Statistics in Medicine|May 4, 2004
The role of the unblinded sponsor statisticianSteven Snapinn, Thomas Cook, Deborah Shapiro, et al.
Pediatric Rheumatology Online Journal|May 15, 2009
Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseasesKirk Sperber, Christine Hom, Chun Peng Chao, et al.
The American Journal of Cardiology|January 17, 2002
Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone)Alise S Reicin, Deborah Shapiro, Rhoda S Sperling, et al.
Comprehensive Therapy|January 15, 2011
Gout and hyperuricemiaChandra S Chilappa, Wilbert S Aronow, Deborah Shapiro, et al.
Gastroenterology|October 3, 2002
Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritisLoren Laine, Claire Bombardier, Christopher J Hawkey, et al.
Cardiovascular Diabetology|January 5, 2013
Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysisSamuel S Engel, Gregory T Golm, Deborah Shapiro, et al.
The Journal of Clinical Endocrinology and Metabolism|July 11, 2002
Lowering low density lipoprotein cholesterol with simvastatin, a hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, does not affect luteal function in premenopausal womenDiane Plotkin, Sam Miller, Steven Nakajima, et al.
Therapeutic Innovation & Regulatory Science|September 18, 2018
Clinical Development Approaches and Statistical Methodologies to Prospectively Assess the Cardiovascular Risk of New Antidiabetic Therapies for Type 2 DiabetesMary Jane Geiger, Cyrus Mehta, J Rick Turner, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
The New England Journal of Medicine|March 18, 2006
Response to expression of concern regarding VIGOR studyAlise Reicin, Deborah Shapiro
Adapted Physical Activity Quarterly : APAQ|February 29, 2024
The Palgrave Handbook of Disability Sport in Europe: Policies, Structures, and ParticipationWellington De Luna-Vazquez, Deborah Shapiro
Statistics in Medicine|May 4, 2004
The role of the unblinded sponsor statisticianSteven Snapinn, Thomas Cook, Deborah Shapiro, et al.
Pediatric Rheumatology Online Journal|May 15, 2009
Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseasesKirk Sperber, Christine Hom, Chun Peng Chao, et al.
The American Journal of Cardiology|January 17, 2002
Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone)Alise S Reicin, Deborah Shapiro, Rhoda S Sperling, et al.
Comprehensive Therapy|January 15, 2011
Gout and hyperuricemiaChandra S Chilappa, Wilbert S Aronow, Deborah Shapiro, et al.
Gastroenterology|October 3, 2002
Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritisLoren Laine, Claire Bombardier, Christopher J Hawkey, et al.
Cardiovascular Diabetology|January 5, 2013
Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysisSamuel S Engel, Gregory T Golm, Deborah Shapiro, et al.
The Journal of Clinical Endocrinology and Metabolism|July 11, 2002
Lowering low density lipoprotein cholesterol with simvastatin, a hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, does not affect luteal function in premenopausal womenDiane Plotkin, Sam Miller, Steven Nakajima, et al.
Therapeutic Innovation & Regulatory Science|September 18, 2018
Clinical Development Approaches and Statistical Methodologies to Prospectively Assess the Cardiovascular Risk of New Antidiabetic Therapies for Type 2 DiabetesMary Jane Geiger, Cyrus Mehta, J Rick Turner, et al.
Pageof 1